Investigation Report on China Pemetrexed Market, 2009-2018
Pemetrexed, originally developed by Eli Lilly and Company, is a multi-targeted antimetabolite antitumor drug. This product is with huge growth potential in the market.
Approved by FDA in February 2004, pemetrexed is to treat unresectable malignant pleural mesothelioma with cisplatin. It is the first drug approved by FDA to treat the disease. In August 2004 pemetrexed was approved as a second-line drug for local or metastatic non-small cell lung cancer.
So far pemetrexed (brand name 'Alimta') has been approved to more than 60 countries worldwide. The product has been a best seller of Eli Lilly and Company since it was launched, and its sales value keeps increasing year after year. The CAGR of sales value of pemetrexed was 50.6% from 2004 to 2011. The sales value was only USD 140 million in 2004 and reached USD 460 million in 2005. In 2011, it grew rapidly to USD 2.46 billion.
In the field of antitumor drugs in China, antimetabolic drug is one of the most common types among traditional anti-tumor chemotherapy drugs. Market size of pemetrexed in China has increased rapidly in recent years. The CAGR of its sales value exceeded 70% from 2006 to 2013.
Pemetrexed was approved to clinical use in China in 2004. It was approved to China in 2005 to treat malignant pleural mesothelioma. As a multi-targeted antimetabolite antitumor drug, pemetrexed can treat non-small cell lung cancer, pancreatic cancer and breast cancer with little side effect. Mechanism of pemetrexed is better than traditional antifolate drugs with great competitiveness in the field.
Hansoh Pharmaceutical and Qilu Pharmaceutical were approved to produce APIs and preparation of this drug respectively in 2005 and 2006. Seeing the great future in the market, a large number of manufacturers start to produce the drug. In 2005, many domestic manufacturers began to apply for the production of raw materials and injections. The competition becomes more intense every day.
From 2005 to 2010, Eli Lilly and Company occupied most of Chinese sample hospital market. However, Qilu Pharmaceutical and Hansoh Pharmaceutical has caught up with Eli Lilly and Company since 2011. The main reason is that drugs made within the country seize more market share with relatively low price. As a result, the market is mostly occupied by Qilu Pharmaceutical, Hansoh Pharmaceutical and Eli Lilly and Company.
By the end of 2013, over 10 manufacturers in China have been approved to produce pemetrexed in China by SFDA. It is estimated that the pemetrexed market in China will become increasingly competitive in the future. As environment pollution intensifies, population aging increases and lifestyle changes, incidence of cancer in China keeps rising, leading to rapid growth in antitumor drug market in China.
Through this report, the readers can acquire the following information:
Approved by FDA in February 2004, pemetrexed is to treat unresectable malignant pleural mesothelioma with cisplatin. It is the first drug approved by FDA to treat the disease. In August 2004 pemetrexed was approved as a second-line drug for local or metastatic non-small cell lung cancer.
So far pemetrexed (brand name 'Alimta') has been approved to more than 60 countries worldwide. The product has been a best seller of Eli Lilly and Company since it was launched, and its sales value keeps increasing year after year. The CAGR of sales value of pemetrexed was 50.6% from 2004 to 2011. The sales value was only USD 140 million in 2004 and reached USD 460 million in 2005. In 2011, it grew rapidly to USD 2.46 billion.
In the field of antitumor drugs in China, antimetabolic drug is one of the most common types among traditional anti-tumor chemotherapy drugs. Market size of pemetrexed in China has increased rapidly in recent years. The CAGR of its sales value exceeded 70% from 2006 to 2013.
Pemetrexed was approved to clinical use in China in 2004. It was approved to China in 2005 to treat malignant pleural mesothelioma. As a multi-targeted antimetabolite antitumor drug, pemetrexed can treat non-small cell lung cancer, pancreatic cancer and breast cancer with little side effect. Mechanism of pemetrexed is better than traditional antifolate drugs with great competitiveness in the field.
Hansoh Pharmaceutical and Qilu Pharmaceutical were approved to produce APIs and preparation of this drug respectively in 2005 and 2006. Seeing the great future in the market, a large number of manufacturers start to produce the drug. In 2005, many domestic manufacturers began to apply for the production of raw materials and injections. The competition becomes more intense every day.
From 2005 to 2010, Eli Lilly and Company occupied most of Chinese sample hospital market. However, Qilu Pharmaceutical and Hansoh Pharmaceutical has caught up with Eli Lilly and Company since 2011. The main reason is that drugs made within the country seize more market share with relatively low price. As a result, the market is mostly occupied by Qilu Pharmaceutical, Hansoh Pharmaceutical and Eli Lilly and Company.
By the end of 2013, over 10 manufacturers in China have been approved to produce pemetrexed in China by SFDA. It is estimated that the pemetrexed market in China will become increasingly competitive in the future. As environment pollution intensifies, population aging increases and lifestyle changes, incidence of cancer in China keeps rising, leading to rapid growth in antitumor drug market in China.
Through this report, the readers can acquire the following information:
- Market Share of Major Pemetrexed Manufacturers in Sample Hospitals in China
- Sales Price of Pemetrexed in China Hospital Market
- Major Pemetrexed Manufacturers in China
- Share of Pemetrexed in Different Dosage Forms in China Hospital Market
- Incidence of Cancer in China
- Manufacturing Schedule of Pemetrexed generic drug
- Prospect of China Pemetrexed Market
- Pemetrexed APIs and Finished Product Manufacturers
- Medical Institutions
- Investors/Research Institutes Focusing on Pemetrexed Market
1 RELEVANT CONCEPTS OF PEMETREXED
1.1 Indication
1.2 Sales Status on the Global Market
2 MARKET OVERVIEW OF PEMETREXED IN CHINA, 2009-2013
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size
3 INVESTIGATION ON SALES VALUE OF PEMETREXED IN CHINA, 2009-2013
3.1 Total Sales Value
3.2 Sales Value by Region
4 INVESTIGATION ON MARKET SHARE OF MAJOR PEMETREXED MANUFACTURERS IN CHINA, 2009-2013
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 INVESTIGATION ON MARKET SIZE OF PEMETREXED BY DOSAGE FORM IN CHINA, 2009-2013
5.1 Market Share by Sales Value and Dosage Form
5.2 Market Share by Sales Volume and Dosage Form
6 REFERENCE PRICE OF PEMETREXED PRODUCED BY DIFFERENT ENTERPRISES IN CHINA HOSPITAL MARKET
6.1 Qilu Pharmaceutical Co., Ltd.
6.2 Hansoh Pharmaceutical
6.3 LILLY France
6.4 Dezhou Pharmaceutical Co., Ltd.
6.5 Nanjing Pharmaceutical Factory Co., Ltd.
6.6 Eli Lilly and Company
6.7 Nanjing Yadong Qitian Pharmaceutical Co., Ltd.
6.8 Jiangsu Aosaikang Pharmaceutical Co., Ltd.
7 PROSPECT OF CHINA PEMETREXED MARKET, 2014-2018
7.1 Forecast on Incidence of Mammary Cancer
7.2 Forecast on Market Size
7.3 Forecast on Competition Pattern
1.1 Indication
1.2 Sales Status on the Global Market
2 MARKET OVERVIEW OF PEMETREXED IN CHINA, 2009-2013
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size
3 INVESTIGATION ON SALES VALUE OF PEMETREXED IN CHINA, 2009-2013
3.1 Total Sales Value
3.2 Sales Value by Region
4 INVESTIGATION ON MARKET SHARE OF MAJOR PEMETREXED MANUFACTURERS IN CHINA, 2009-2013
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 INVESTIGATION ON MARKET SIZE OF PEMETREXED BY DOSAGE FORM IN CHINA, 2009-2013
5.1 Market Share by Sales Value and Dosage Form
5.2 Market Share by Sales Volume and Dosage Form
6 REFERENCE PRICE OF PEMETREXED PRODUCED BY DIFFERENT ENTERPRISES IN CHINA HOSPITAL MARKET
6.1 Qilu Pharmaceutical Co., Ltd.
6.2 Hansoh Pharmaceutical
6.3 LILLY France
6.4 Dezhou Pharmaceutical Co., Ltd.
6.5 Nanjing Pharmaceutical Factory Co., Ltd.
6.6 Eli Lilly and Company
6.7 Nanjing Yadong Qitian Pharmaceutical Co., Ltd.
6.8 Jiangsu Aosaikang Pharmaceutical Co., Ltd.
7 PROSPECT OF CHINA PEMETREXED MARKET, 2014-2018
7.1 Forecast on Incidence of Mammary Cancer
7.2 Forecast on Market Size
7.3 Forecast on Competition Pattern
SELECTED CHARTS
Chart Pemetrexed Products Approved to Market in China by 2014
Chart Forecast on Market Size of Hospital-use Pemetrexed in China, 2014-2018
Chart Sales Value of Pemetrexed in Global Market, 2009-2013
Chart Sales Value of Pemetrexed in Hospital Market in China, 2009-2013
Chart Sales Value of Pemetrexed by Region in China, 2009-2013
Chart Market Share of Pemetrexed Enterprises by Sales Value in China, 2009-2013
Chart Price of Pemetrexed Produced by Qilu Pharmaceutical Co., Ltd. in China Hospital Market, 2009-2013
Chart Price of Pemetrexed Produced by Hansoh Pharmaceutical in China Hospital Market, 2009-2013
Chart Price of Pemetrexed (Alimta) Produced by LILLY France in China Hospital Market, 2009-2013
Chart Pemetrexed Products Approved to Market in China by 2014
Chart Forecast on Market Size of Hospital-use Pemetrexed in China, 2014-2018
Chart Sales Value of Pemetrexed in Global Market, 2009-2013
Chart Sales Value of Pemetrexed in Hospital Market in China, 2009-2013
Chart Sales Value of Pemetrexed by Region in China, 2009-2013
Chart Market Share of Pemetrexed Enterprises by Sales Value in China, 2009-2013
Chart Price of Pemetrexed Produced by Qilu Pharmaceutical Co., Ltd. in China Hospital Market, 2009-2013
Chart Price of Pemetrexed Produced by Hansoh Pharmaceutical in China Hospital Market, 2009-2013
Chart Price of Pemetrexed (Alimta) Produced by LILLY France in China Hospital Market, 2009-2013
